The transcription factor C/EBP delta has anti-apoptotic and anti-inflammatory roles in pancreatic beta cells by Moore, Fabrice et al.
The Transcription Factor C/EBP delta Has Anti-Apoptotic
and Anti-Inflammatory Roles in Pancreatic Beta Cells
Fabrice Moore1*, Izortze Santin1, Tatiane C. Nogueira1, Esteban N. Gurzov1, Lorella Marselli2, Piero
Marchetti2, Decio L. Eizirik1*
1 Laboratory of Experimental Medicine, Universite´ Libre de Bruxelles, Brussels, Belgium, 2Metabolic Unit, Department of Endocrinology and Metabolism, University of
Pisa, Pisa, Italy
Abstract
In the course of Type 1 diabetes pro-inflammatory cytokines (e.g., IL-1b, IFN-c and TNF-a) produced by islet-infiltrating
immune cells modify expression of key gene networks in b-cells, leading to local inflammation and b-cell apoptosis. Most
known cytokine-induced transcription factors have pro-apoptotic effects, and little is known regarding ‘‘protective’’
transcription factors. To this end, we presently evaluated the role of the transcription factor CCAAT/enhancer binding
protein delta (C/EBPd) on b-cell apoptosis and production of inflammatory mediators in the rat insulinoma INS-1E cells, in
purified primary rat b-cells and in human islets. C/EBPd is expressed and up-regulated in response to the cytokines IL-1b and
IFN-c in rat b-cells and human islets. Small interfering RNA-mediated C/EBPd silencing exacerbated IL-1b+IFN-c-induced
caspase 9 and 3 cleavage and apoptosis in these cells. C/EBPd deficiency increased the up-regulation of the transcription
factor CHOP in response to cytokines, enhancing expression of the pro-apoptotic Bcl-2 family member BIM. Interfering with
C/EBPd and CHOP or C/EBPd and BIM in double knockdown approaches abrogated the exacerbating effects of C/EBPd
deficiency on cytokine-induced b-cell apoptosis, while C/EBPd overexpression inhibited BIM expression and partially
protected b-cells against IL-1b+IFN-c-induced apoptosis. Furthermore, C/EBPd silencing boosted cytokine-induced
production of the chemokines CXCL1, 9, 10 and CCL20 in b-cells by hampering IRF-1 up-regulation and increasing STAT1
activation in response to cytokines. These observations identify a novel function of C/EBPd as a modulatory transcription
factor that inhibits the pro-apoptotic and pro-inflammatory gene networks activated by cytokines in pancreatic b-cells.
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Introduction
Type 1 diabetes (T1D) is a multi-factorial disease where a
chronic autoimmune assault results in a progressive b-cell loss and
increased circulating blood glucose levels [1,2]. The recent
discovery of numerous T1D-associated susceptibly genes [3,4],
as well as T1D-predisposing environmental factors [5,6], added
new layers of complexity to our understanding of the disease.
Pancreatic islet infiltration by activated immune cells and the
development of an aberrant islet inflammation (insulitis) are
assumed to represent common events in early T1D [1,2,7]. A
detailed understanding of early insulitis, during which infiltrating
autoimmune cells induce b-cell apoptosis and inflammation [1,8],
may indicate novel and rational approaches for therapeutic
interventions [9–11].
The pro-inflammatory cytokines interleukin(IL)-1b, interfero-
n(IFN)-c and tumor necrosis factor(TNF)-a produced by infiltrat-
ing immune cells play a critical role in the progression of b-cell
demise and apoptosis in T1D [1,8,12–14]. We previously
demonstrated that these pro-inflammatory cytokines activate the
transcription factors NF-kB, STAT1 and IRF-1 in b-cells, and
performed a series of microarray analysis to determine the gene
networks regulated by these transcription factors in b-cells
[13,15,16]. Down-regulated genes targeted by the pro-inflamma-
tory cytokines and regulated by NF-kB/STAT1 include genes
associated with b-cell differentiation (e.g. MafA, Pdx1, Isl1 and
Nkx2.2) and function (e.g. insulin, Glut2, glucokinase, proconver-
tase 1 and 3) [13,16]. On the other hand there is up-regulation of
genes implicated in endoplasmic reticulum(ER)-stress, e.g. XBP-1s,
ATF6 and CHOP (GADD153, Ddit3, C/EBPf) [17–19], and of
inflammation-promoting genes, such as the CXC chemokines
CXCL1, 9, 10 and the CC chemokines CCL2, 5 and 20 [16,20].
b-cell production of chemokines may play a key role in the
initiation [21] and persistence of insulitis in murine and human
diabetes [1,22]. Cytokine-induced chemokine production is tightly
regulated by STAT1 in b-cells, while its downstream transcription
factor IRF-1 exerts inhibitory effects on chemokine production
through activation of the negative regulator SOCS-1 [16].
Combinations of IL-1b or TNF-a with IFN-c also induce a major
shift in the balance between the pro- and anti-apoptotic members
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of the apoptosis-regulating genes B cell lymphoma 2 (Bcl-2) family
in b-cells [23], with Death Protein 5 (DP5) [24], BCL2 binding
component 3 (BBC3/PUMA) [25] and BCL2-like 11 (BIM)
[26,27] contributing to cytokine-induced b-cells apoptosis. Cyto-
kine-induced b-cell apoptosis occurs through the ‘‘intrinsic’’
mitochondrial pathway, involving translocation of the pro-
apoptotic protein Bax to the mitochondria, depolarization of the
mitochondrial membrane, cytochrome c release and activation of
caspases 9 and 3 [23].
Further analysis of our microarray data pointed out to an early
induction of the transcription factor CCAAT/enhancer binding
protein delta (C/EBPd) in cytokine-treated b-cell via NF-kB and
STAT1 activation [13,15,16]. The role for this transcription factor
in b-cell, however, remains to be clarified. The C/EBP family
consists of six transcription factors (a, b, c, d, e and f) sharing a
highly conserved basic leucin zipper domain at the C-terminal
region of the protein; this domain is involved in homo- or hetero-
dimerization and in DNA binding activity [28]. C/EBPd
expression is induced in other cell types in response to various
stimuli, including mitogens, hormones, toxins and cytokines (IL-
1b, IL-6, IFN-c), and is mostly regulated at the transcriptional
level [28]. Unlike C/EBPa, b and e that exist as different splicing
variants displaying diverse functions [29,30], only one C/EBPd
isoform has been identified in rodents and humans [28]. C/EBPd
dimerises with several members of the C/EPB family (a, b and f)
but also with NF-kB1 p50, RelA, and the Ets family member
PU.1. [31–34], allowing it to exert various functions in different
cell types. C/EBPd activities have been associated with adipocytes
differentiation [35], learning and memory processes in neurons
[36], tumor suppressor activities in mammary gland epithelial cells
[37,38] and with Toll-like Receptor-mediated production of pro-
inflammatory cytokines in macrophages [39], but much less is
known about this transcription factor as compared to other
members of the C/EBP family [28].
We presently report that C/EBPd is expressed in rat insulinoma
cells, primary rat b-cells and human islets, and that its expression is
up-regulated upon exposure to IL-1b+IFN-c. Using several single
and combined siRNA-mediated knockdown approaches, we
demonstrate that C/EBPd deficiency exacerbates cytokine-
induced b-cell demise by promoting pro-apoptotic and pro-
inflammatory signalling pathways. Likewise, C/EBPd overexpres-
sion partially protects b-cells against cytokine-induced apoptosis.
All together, these results identify C/EBPd as a new transcription
factor that exerts unique and non-redundant functions in b-cells
by negatively regulating the deleterious effects of pro-inflamma-
tory cytokines.
Results
The cytokines IL-1b and IFN-c up-regulate C/EBPd mRNA
and protein expression in INS-1E cells, primary rat b-cells
and human islets
Our previous microarray data suggest that C/EBPd expression
is modified by cytokine treatment in rat b-cells [13,15,16,40]. In
order to validate these observations, we evaluated C/EBPd
mRNA and protein expression in the rat insulinoma INS-1E
cells, in primary FACS-sorted rat b-cells and human islets exposed
to cytokines. C/EBPdmRNA expression was up-regulated already
after 4 h of IL-1b+IFN-c treatment in INS-1E cells, reaching a
peak at 8 h (6-fold increase) and remaining increased until 24 h.
On the other hand, the combination of TNF-a+IFN-c did not
induce C/EBPd expression at any of the tested time points
(Figure 1A). Treatment of INS-1E cells for 8 h with each
individual cytokine identified IL-1b as the key inducer of C/
EBPd expression; IFN-c had no effect on its own, but it amplified
IL-1b-induced C/EBPd up-regulation (Figure 1B). Western blot
analysis in INS-1E cells corroborated these observations, since C/
EBPd proteins were up-regulated by respectively 2- and 5-fold
after 8 h of IL-1b and IL-1b+IFN-c exposure (Figure 1C;
densitometry in Figure S1A). These observations were confirmed
in FACS-purified primary rat b-cells, in which IL-1b+IFN-c
induced a 3- and 10-fold up-regulation of C/EBPd expression
after 12 and 24 h respectively (Figure 1D) while its expression was
unaffected by TNF-a+IFN-c treatment (Figure S1B). In human
islet cells, a 24 h exposure to IL-1b+IFN-c up-regulated both C/
EBPd mRNA and protein expressions by 2–3 fold (Figure 1E–G).
We also confirmed the role of the transcription factors NF-kB and
STAT1 in cytokine-induced C/EBPd up-regulation in b-cells
[15,16]. Thus, NF-kB blockade using a super-repressor IkBa
inhibited IL-1b+IFN-c-induced C/EBPd transcription until 24 h
(Figure S1C), while siRNA-mediated STAT1 knockdown affected
mostly the early (12 h) up-regulation of C/EBPd by cytokines
(Figure S1D).
siRNA-mediated C/EBPd silencing exacerbates cytokine-
induced apoptosis in INS-1E cells, primary rat b-cells, and
dispersed human islets
We next used a siRNA-mediated knockdown approach to
evaluate a putative role for C/EBPd in IL-1b+IFN-c-induced b-
cell apoptosis. INS-1E cells were transfected with an irrelevant
control siRNA (siCtrl) or with two siRNAs targeting C/EBPd
(siC/EBPd #1 and #2). Cells were subsequently left untreated,
or treated for 2 to 24 h with IL-1b+IFN-c. Cytokines induced C/
EBPd protein up-regulation, reaching a peak at 8 h and slowly
decreasing until 24 h (Figure 2A and 2B). The two siRNAs
targeting C/EBPd accurately silenced its expression in both
untreated and IL-1b+IFN-c-treated cells (Figure 2A and 2B). As
previously reported [8,16], treatment with IL-1b+IFN-c induced
apoptosis in siCtrl-transfected INS-1E cells after 24 h and in
primary b-cells after 48 h (Figure 2C & 2D), while inducing
necrosis in few cells under all experimental conditions tested
(,2% necrotic cells - data not shown). C/EBPd silencing with the
two siRNAs exacerbated INS-1E cell and primary b-cell
apoptosis after exposure to IL-1b+IFN-c (Figure 2C & 2D). This
increased apoptosis was confirmed in INS-1E cells by a second
method that detects cytoplasmic fragmented DNA (Figure 2E). In
line with these observations, quantification of the remaining
living cells by neutral red confirmed that C/EBPd deficiency
hampered the ability of the cells to survive the IL-1b+IFN-c
treatment (Figure 2F). On the other hand, C/EBPd mRNA
silencing did not induce apoptosis in untreated INS-1E cells or
after treatments with IL-1b or IFN-c alone (Figure S2A), and it
neither exacerbated apoptosis (Figure S2B) nor decreased the
survival (Figure S2C) of INS-1E cells exposed to the combination
of TNF-a+IFN-c. The enhanced apoptosis in IL-1b+IFN-c-
treated C/EBPd-silenced b-cells could not be explained by a
higher production of nitric oxide (NO), since nitrite was similarly
produced by siCtrl- and siC/EBPd-transfected cells after IL-
1b+IFN-c exposure in primary rat b-cells (Figure 2G) and INS-
1E cells (Figure S2D). Furthermore, the production of intracel-
lular reactive oxygen- or nitrogen species (ROS or RNS) was also
similar in cytokine-treated siCtrl- and siC/EBPd-transfected INS-
1E cells (Figure S2E). These data suggest that the increased
cytokine-induced apoptosis in C/EBPd-silenced cells is probably
not due to an amplified oxidative/nitrosative stress. Viability
assays in dispersed human islet cells also demonstrated that
efficient silencing of C/EBPd with three different siRNAs
(Figure 2H & Figure S2F) resulted in increased apoptotic cell
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death after 48 h of IL-1b+IFN-c exposure (Figure 2I). Cytokine-
triggered b-cell apoptosis occurs through the mitochondrial-
dependent intrinsic pathway of cell death, involving the
translocation of the pro-apoptotic protein Bax to the mitochon-
dria, cytochrome c release from the mitochondria to the
cytoplasm, and subsequent cleavage and activation of caspases
9 and 3 [17,23,24]. As shown in Figure S2G, IL-1b+IFN-c-
induced apoptosis in C/EBPd-silenced cells followed the same
pathway, with Bax staining showing strong co-localization with
the mitochondrial marker ATP synthase in apoptotic cells
(arrow), while it was weak and diffuse in living cells (Figure
S2G). Moreover, cytochrome c staining co-localized with the
mitochondrial marker AIF in siC/EBPd-transfected living cells,
while apoptotic cells had diffuse cytoplasmic cytochrome c
staining (arrow), suggesting cytochrome c release from the
mitochondria (Figure S2H). Western blot analysis demonstrated
that cytokine-induced expression of cleaved caspase 9 and
caspase 3 were enhanced in siC/EBPd-transfected cells as
compared to siCtrl-transfected counterparts (Figure 2J – densi-
tometries are shown in Figures S2I & S2J), supporting the
observations from the viability assays (Figure 2C & 2D) and
confirming the involvement of the mitochondrial pathway. We
next performed glucose oxidation tests to evaluate the putative
role of C/EBPd on the functional inhibition of b-cells induced by
cytokines [8,13,16]. Cytokine treatment greatly reduced the
ability of b-cells to oxidize glucose (Figure S2K). The inhibition of
glucose oxidation was, however, similar in cytokine-treated siCtrl-
and siC/EBPd-transfected cells (Figure S2K), suggesting that C/
EBPd is not involved in inhibition of b-cell function.
We also evaluated a putative role of C/EBPb in cytokine-
induced b-cell death. This other member of the C/EBP family was
previously shown to be up-regulated by cytokines in array analysis
of cytokine-treated b-cells [13,16] and to modulate mouse b-cell
susceptibility to ER stress [41]. The expression of C/EBPb was
up-regulated in INS-1E and primary b-cells after 12–24 h of IL-
1b+IFN-c exposure (Figure S3A) [13,16]. A 36–60% silencing of
C/EBPb using two different siRNAs (Figure S3B) did not affect
cytokine-induced apoptosis in INS-1E cells (Figure S3C) while it
slightly decreased NO production (Figure S3D).
C/EBPd knockdown enhances cytokine-induced CHOP
expression and transcriptional activity in b-cells
To clarify the molecular pathways underlying the exacerbation
of cytokine-induced apoptosis in C/EBPd-silenced cells, we first
evaluated the expression of several genes induced during ER
stress, a cellular response associated with IL-1b+IFN-c-induced
apoptosis in b-cells [18,42]. XBP-1s mRNA expression was
similarly up-regulated by cytokine treatment in siCtrl- and siC/
EBPd-transfected INS-1E cells and C/EBPd silencing did not
induce nuclear translocation of XBP-1s in cytokine-treated INS-
1E cells (data not shown). Cytokine treatment equally decreased
Bip mRNA expression at 24 h in the three transfected conditions.
On the other hand, C/EBPd deficiency enhanced IL-1b+IFN-c-
induced CHOP mRNA up-regulation after 8- and 16 h in INS-1E
Figure 1. IL-1b and IFN-c up-regulate C/EBPd expression in INS-1E cells, primary rat b-cells and human islets. INS-1E cells (A–C), primary
purified rat b-cells (D) or human islets (E–G) were left untreated or treated with either IL-1b, IFN-c, TNF-a, IL-1b+IFN-c or TNF-a+IFN-c for the indicated
time points. (A, B, D, E) C/EBPd mRNA expression was assayed by RT-PCR and normalized for the housekeeping gene GAPDH (rat) or b-actin (human);
(C, F) C/EBPd and a-tubulin expressions were evaluated by Western blot. A representative experiment of 5–6 independent experiments is shown. (G)
Mean optical density measurements of C/EBPd Western blots corrected for protein loading by a-tubulin (representative figure in F). Results are mean
6 SEM of 4–6 independent experiments; * p,0.05, ** p,0.01 and *** p,0.001 vs untreated cells by Student’s t test.
doi:10.1371/journal.pone.0031062.g001
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cells (Figure 3A & 3B). This increased CHOP expression was
confirmed at the protein level after 16- and 24 h of cytokine
treatment (Figure 3D & 3E) and had a functional impact, since the
expression of the CHOP-dependent gene GADD34 was also
augmented by C/EBPd silencing in INS-1E cells (Figure 3C).
Since CHOP is a member of the C/EBP family (C/EBPf) [28]
and may hetero-dimerize with C/EBPd [43], we next evaluated a
putative role of CHOP in the exacerbation of cytokine-induced
apoptosis in C/EBPd-silenced cells. To this end, we interfered in
parallel with C/EBPd and CHOP expressions, in a double
knockdown approach, and performed viability assays. As de-
scribed above, C/EBPd deficiency exacerbated IL-1b+IFN-c-
induced apoptosis in INS-1E cells, while CHOP silencing had no
effect on cell apoptosis after 24 h of cytokine treatment (Figure 3F).
Interestingly, the concomitant knockdown of CHOP abrogated
the exacerbating effect of C/EBPd silencing on apoptosis
(Figure 3F). These results were confirmed by Western blot for
cleaved caspase 3: the simultaneous inhibition of C/EBPd and
CHOP reversed the increased expression of cleaved caspase 3
observed after C/EBPd silencing (Figure 3G). These results
identify CHOP as a contributory factor in the exacerbation of
cytokine-induced apoptosis in C/EBPd-silenced b-cells. Since
CHOP may also regulate the mitochondrial Unfolded Protein
Response (UPRmt) [44], we evaluated whether C/EBPd silencing
exacerbates the UPRmt. This was done by evaluating the
expression of LONP1, ClpP and HSP60, well-known markers of
Figure 2. C/EBPd silencing exacerbates cytokine-induced apoptosis in rat b-cells and human islets. (A, B, C, E, F) INS-1E cells were
transfected with either a control siRNA (siCtrl – white dots/bars), or two differents siRNAs targeting C/EBPd (siC/EBPd #1 – black triangles/bars and
siC/EBPd #2 – grey squares/bars). Cells were then left untreated, or treated with IL-1b+IFN-c as indicated; (A) C/EBPd and a-tubulin expressions were
evaluated by Western blot; (B) Mean optical density measurements of C/EBPd Western blots corrected for a-tubulin (representative figure in A); (C)
Apoptosis was assessed by HO/PI staining; (E) Apoptosis was evaluated using the Cell Death Detection ELISAplus kit; (F) Cell viability was evaluated
using the neutral red-based toxicology kit. (D, G) Primary FACS-sorted rat b-cells were transfected as described above and subsequently left untreated
or treated with IL-1b+IFN-c as indicated; (D) Apoptosis was assessed by HO/PI staining. (G) Nitrite concentrations in supernatants were measured as
described in Methods. (H–I) Dispersed human islets were transfected with siCtrl (white bars) or human siC/EBPd #1 (black bars) or #2 (grey bars) or
#3 (hatched bars) and subsequently treated with IL-1b+IFN-c for 48 h; (H) C/EBPd mRNA expression was assayed by RT-PCR and normalized for the
housekeeping gene b-actin; (I) Apoptosis was assessed by HO/PI staining. (J) INS-1E cells were transfected with siCtrl or siC/EBPd #1; Cleaved caspase
3, 9 and a-tubulin expressions were evaluated by Western blot. Results are mean 6 SEM of 4–7 experiments; *: p,0.05, **: p,0.01 and ***: p,0.001
vs untreated transfected with the same siRNA; 1: p,0.05, 11: p,0.01 and 111: p,0.001 vs siCtrl treated with cytokines at the same time point;
ANOVA followed by Student’s t test with Bonferroni correction.
doi:10.1371/journal.pone.0031062.g002
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the UPRmt [44]. There were not, however, noticeable differences
in the regulation of these three UPRmt markers in cytokine-treated
C-EBPd-deficient INS-1E cells as compared to their control
counterparts (Figure S4C), making it unlikely that the UPRmt play
a major role in the pro-apoptotic effect of C/EBPd-silencing.
The expression of the pro-apoptotic protein BIM is up-
regulated in C/EBPd-silenced cells
We next evaluated the effect of C/EBPd knockdown on the
mRNA expression of pro-apoptotic members of the Bcl-2 family
associated with cytokine-induced b-cell apoptosis [23–25]. The
Figure 3. Amplified CHOP expression contributes to the exacerbation of apoptosis in cytokine-treated C/EBPd-deficient INS-1E
cells. (A–E) INS-1E cells were transfected with siCtrl (white dots), siC/EBPd #1 (black triangles) or siC/EBPd #2 (grey squares) and subsequently left
untreated, or treated with IL-1b+IFN-c for the indicated time points. (A–C) C/EBPd, CHOP and GADD34 mRNA expressions were assayed by RT-PCR
and normalized for the housekeeping gene GAPDH; (D) C/EBPd, CHOP and a-tubulin expressions were evaluated by Western blot. (E) Mean optical
density measurements of CHOP Western blots corrected for a-tubulin (representative figure in D). (F–G) INS-1E cells were transfected with siCtrl
(white bars), siC/EBPd #1 (black bars), siCHOP (grey bars) or siC/EBPd #1+siCHOP (hatched grey bars) and subsequently left untreated, or treated
with IL-1b+IFN-c for 24 h as indicated. (F) Apoptosis was assessed by HO/PI staining. (G) Cleaved caspase 3, C/EBPd, CHOP and a-tubulin expressions
were evaluated by Western blot. Results are mean 6 SEM of 4–5 experiments; *: p,0.05, **: p,0.01 and ***: p,0.001 vs untreated transfected with
the same siRNA; 1: p,0.05, 11: p,0.01 and 111: p,0.001 vs siCtrl treated with cytokines at the same time point; ##: p,0.01 vs siC/EBPd #1 treated
with cytokines at the same time point; ANOVA followed by Student’s t test with Bonferroni correction.
doi:10.1371/journal.pone.0031062.g003
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expression of DP5, PUMA and BIM mRNAs were all induced by
IL-1b+IFN-c in INS-1E cells, reaching a peak after 16 h of
cytokine treatment (Figure 4A & Figure S5A & S5B). Interestingly,
the cytokine-induced up-regulation of BIM mRNA was exacer-
bated by C/EBPd silencing (Figure 4A), while C/EBPd deficiency
did not affect the induction of DP5 and PUMA mRNAs following
cytokine treatment (Figure S5A & S5B). Of note, the cytokine-
induced up-regulation of the anti-apoptotic Bcl-2 family member
B-cell lymphoma-extra large (Bcl-XL) was also unaffected by C/
EBPd knockdown (Figure S5C). BIM expression at the protein
level was stable between 8 and 16 h in cytokine-treated C/EBPd-
silenced cells while it decreased in siCtrl-transfected cells at 8 h
(Figure 4B & 4C). This decrease in BIM expression in siCtrl-
transfected cells after 8 h of cytokine treatment is probably not due
to an off-target effect of the siCtrl, since a similar decrease in BIM
expression was observed in untransfected INS-1E cells after 8 h of
IL-1b+IFN-c exposure (Figures S5D et S5E). As a whole, the data
described above suggest that BIM plays a key role in the
sensitization of C/EBPd-silenced cells to the pro-apoptotic effects
of cytokines. To test this hypothesis, we performed viability assays
after parallel knockdown of C/EBPd and BIM. BIM inhibition
partially prevented IL-1b+IFN-c-induced apoptosis in INS-1E
cells (Figure 4D), while the double inhibition of C/EBPd and BIM
abrogated the potentiating effects of C/EBPd knockdown on
cytokine-induced apoptosis (Figure 4D), suggesting that increased
BIM activity contributes for the exacerbation of apoptosis in
cytokine-treated C/EBPd silenced cells.
C/EBPd inhibition increases cytokine-induced b-cell
chemokine production through defective control of
STAT1 transcriptional activity
b-cells produce many chemokines from the CXC and CC
families in response to IL-1b+IFN-c exposure, hence contributing
to attract and activate immune cells during insulitis [1]. Taking
this into account, we evaluated whether C/EBPd also modulates
the inflammatory response in IL-1b+IFN-c-exposed cells. C/
EBPd silencing exacerbated the expression of CXCL1, 9, 10 and
CCL20 mRNAs after 16 h of cytokine exposure (Figure 5A–E).
These data were at least in part confirmed at the protein level,
since C/EBPd-silenced cells secreted higher amounts of the
chemokines CXCL1 and CXCL9 as compared to control cells
after 16- and 24 h of cytokine treatment (Figure 5F & 5G). Since
we previously identified that the STAT1/IRF-1 signalling
pathway exerts a key role in cytokine-induced chemokine
production in b-cells [16], we performed time course analysis of
the expression of these transcription factors in Ctrl- and C/EBPd-
deficient INS-1E cells after cytokine exposure. Interestingly, C/
EBPd silencing hampered cytokine-induced IRF-1 expression
(Figure 5H & 5J). As previously shown [16], this impaired IRF-1
expression was accompanied by exacerbated STAT1 phosphor-
ylation after 8 h of treatment with IL-1b+IFN-c, but also by
increased expression of total STAT1 after 8, 16 and 24 h of
cytokine treatment (Figure 5H, 5K & 5L). This prolonged STAT1
activation in C/EBPd-silenced cells enhanced STAT1 transcrip-
tional activity, as shown by IL-1b+IFN-c-induced augmented
Figure 4. C/EBPd-silencing increases the expression of the pro-apoptotic Bcl-2 family member BIM. (A–C) INS-1E cells were transfected
with siCtrl (white dots), siC/EBPd #1 (black triangles) or siC/EBPd #2 (grey squares) and subsequently left untreated, or treated with IL-1b+IFN-c for
the indicated time points. (A) BIM mRNA expression was assayed by RT-PCR and normalized for the housekeeping gene GAPDH; (B) BIM, C/EBPd and
a-tubulin expressions were evaluated by Western blot. (C) Mean optical density measurements of BIM Western blots corrected for a-tubulin
(representative figure in B). (D) INS-1E cells were transfected with siCtrl (white bars), or with either siC/EBPd #1 (black bars), siBIM (grey bars) or siC/
EBPd #1+siBIM (hatched grey bars) and subsequently left untreated, or treated with IL-1b+IFN-c for 24 h as indicated. Apoptosis was then assessed
by HO/PI staining. Results are mean6 SEM of 4–6 experiments; *: p,0.05, **: p,0.01 and ***: p,0.001 vs untreated transfected with the same siRNA;
1: p,0.05, 11: p,0.01 and 111: p,0.001 vs siCtrl treated with cytokines at the same time point;###: p,0.001 vs siC/EBPd#1 treated with cytokines
at the same time point; ANOVA followed by Student’s t test with Bonferroni correction.
doi:10.1371/journal.pone.0031062.g004
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Figure 5. C/EBPd silencing increases cytokine-induced chemokine production by enhancing STAT1 activation. INS-1E cells were
transfected with either siCtrl (white dots/bars), siC/EBPd#1 (black triangles/bars) or siC/EBPd#2 (grey squares/bars) and subsequently left untreated,
or treated with IL-1b+IFN-c for the indicated time points; (A–E) C/EBPd, CXCL1, 9, 10 & CCL20 mRNA expressions were assayed by RT-PCR and
normalized for the housekeeping gene GAPDH; (F–G) CXCL1 and CXCL9 protein secretions were evaluated by ELISA. (H) C/EBPd, phospho-STAT1,
total STAT1, IRF-1 and a-tubulin expressions were evaluated by Western blot. (I) 24 h after siRNA transfection, cells were transfected with a STAT1
luciferase reporter+pRL-CMV and subsequently left untreated or exposed to cytokines for 16 h as indicated. Results are mean Relative Luciferase Unit
(R.L.U.) 6 SEM. (J–L) Mean optical density measurements of IRF1, phospho-STAT1 and total STAT1 Western blots corrected for a-tubulin
(representative figure in H). (G) SOCS-1 mRNA expression was assayed by RT-PCR and normalized for the housekeeping gene GAPDH. Results are
mean 6 SEM of 4–6 experiments; *: p,0.05, **: p,0.01 and ***: p,0.001 vs untreated transfected with the same siRNA; 1: p,0.05, 11: p,0.01 and
111: p,0.001 vs siCtrl treated with cytokines at the same time point; ANOVA followed by Student’s t test with Bonferroni correction.
doi:10.1371/journal.pone.0031062.g005
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activation of a STAT1 reporter in C/EBPd-silenced cells as
compared to controls (Figure 5I). This effect is specific, since C/
EBPd knockdown had an opposite effect on an NF-kB reporter,
inducing a 20–50% decrease (Figure S6). We next evaluated the
expression of SOCS-1, a negative regulator of STAT1 activity that
is modulated by IRF-1 activation in b-cells [16]. As shown in
Figure 5M, cytokine-induced SOCS-1 up-regulation was also
impaired in C/EBPd-silenced cells as compared to Ctrl, reflecting
the impaired activation of IRF-1 in C/EBPd-deficient cells. All
together, these results demonstrate that C/EBPd exacerbates
cytokine-induced chemokine production by interfering with IRF-1
up-regulation, hence disturbing the negative regulatory feedback
loop by which IRF-1 modulates STAT1 activation through the
induction of the inhibitory protein SOCS-1 [16].
The transcription factors CHOP and STAT1 contribute to
the enhancement of BIM expression in C/EBPd-silenced
cells
We described above that the activation of the transcription
factors CHOP and STAT1 are increased or prolonged in C/
EBPd-silenced cells (Figure 3D–E and Figure 5H–L). Since both
CHOP and STAT1 have been reported to mediate BIM
transcriptional regulation in thymocytes and b-cells respectively
[26,45], we next evaluated a putative role of these transcription
factors in the exacerbation of BIM expression in C/EBPd-silenced
b-cells. To this end, INS-1E cells were transfected with previously
validated siRNAs targeting C/EBPd (Figure 2A–B), CHOP
(Figure 3G) and STAT1 [16,46] alone or in combination, and
the expression of BIM mRNA evaluated. As shown in Fig. 6A–C,
the individual siRNAs inhibited their target gene without affecting
the expression of the other non-targeted genes evaluated. As
described in Figures 3 and 4, C/EBPd silencing exacerbated
CHOP and BIM up-regulation as compared to controls after 16 h
of cytokine treatment (Figure 6A & 6D), while the knockdown of
CHOP alone had no effect on cytokine-induced BIM expression
(Figure 6D). Interestingly, the double knockdown of C/EBPd and
CHOP reversed to a large extent the exacerbation of BIM
expression induced by C/EBPd silencing alone (Figure 6D).
STAT1 silencing, alone or in combination with C/EBPd
inhibition, potently inhibited IL-1b+IFN-c-induced BIM up-
regulation (Figure 6D). The double knockdown of CHOP and
STAT1 did not further inhibit cytokine-induced BIM expression
as compared to STAT1 silencing alone (Figure 6D). We next
studied the regulation of the rat BIM promoter using a luciferase
reporter construct containing the complete sequence of the this
promoter (22454/+2658) [47]. To this end, INS-1E cells were
successively transfected with specific siRNAs as indicated and then
with the rat BIM luciferase reporter. C/EBPd silencing augmented
the up-regulation of the BIM promoter induced by IL-1b+IFN-c
treatment as compared to siCtrl-transfected cells, while the
concomitant knockdown of C/EBPd and CHOP reversed the
exacerbating effect of C/EBPd silencing on the induction of the
BIM promoter (Figure 6E). The siSTAT1, alone or associated with
C/EBPd or CHOP inhibition also prevented cytokine-induced up-
regulation of the BIM promoter (Figure 6E). Viability assays
corroborated these observations, with CHOP silencing inhibiting
the exacerbating pro-apoptotic effects of C/EBPd inhibition in
cytokine-treated INS-1E cells, while STAT1 silencing both
protected the cells against cytokine-induced apoptosis and
counteracted the pro-apoptotic effects of C/EBPd silencing
(Figure 6F). Theses results identify STAT1 as a key mediator of
IL-1b+IFN-c-induced BIM up-regulation in b-cells, and suggest
that the transcription factor CHOP mediates the ‘‘exacerbating
effect’’ of C/EBPd silencing on cytokine-induced BIM up-
regulation.
C/EBPd overexpression decreases BIM expression and
partially protects INS-1E cells against cytokine-induced
apoptosis
We next tested whether C/EBPd overexpression affects BIM
expression in INS-1E cells. Interestingly, a strong overexpression
of C/EBPd (Figure 7A) reduced both basal and cytokine-induced
BIM expression (Figure 7A & 7B) and also decreased IL-1b+IFN-
c-induced up-regulation of BIM and CHOP mRNA expressions
(Figure 7C & 7D). The co-tranfection of the C/EBPd overexpres-
sion vector with the rat BIM promoter also reduced cytokine-
induced up-regulation of this promoter as compared to untran-
fected- and control-transfected counterparts (Figure 7E). Finally,
viability experiments demonstrated that C/EBPd overexpression
induced a moderate protection against IL-1b+IFN-c-induced
apoptosis (Figure 7F), and increased the survival of INS-1E cells
as compared to control-transfected cells (Figure 7G). Taken
together, these experiments support the hypothesis that C/EBPd
inhibits BIM expression and thus partially counteracts cytokine-
induced apoptosis.
Discussion
A better understanding of the signalling pathways involved in
cytokine-induced b-cell apoptosis during insulitis may help to
define potential therapeutic targets to interfere with T1D
development [9]. We presently demonstrate, using silencing and
overexpression approaches, that the transcription factor C/EBPd
is up-regulated by IL-1b+IFN-c in rat b-cells and human islets and
exerts regulatory functions in these cells, inhibiting pro-apoptotic
and pro-inflammatory signals (Figure 8). NF-kB plays an
important role in cytokine-induced C/EBPd expression, as IL-1b
(a known NF-kB inducer) up-regulates C/EBPd expression in b-
cells, while NF-kB blockade inhibits cytokine-induced C/EBPd
mRNA up-regulation (present data; [15]). These results are in line
with previous observations describing NF-kB recruitment at the
C/EBPd promoter after 1 h of LPS exposure in macrophages
[48]. The transcription factor STAT1 is also involved in cytokine-
induced C/EBPd expression, since IFN-c enhances IL-1b-
induced-C/EBPd up-regulation and interfering with STAT1
activity hampers cytokine-induced C/EBPd expression at early
time points (Figure S1D; [16]). It is surprising, however, that the
combination of TNF-a+IFN-c does not up-regulate C/EBPd
expression in b-cells, and likewise, that C/EBPd silencing or
overexpression does not affect TNF-a+IFN-c-induced cells death
in b-cells (Figure S2B–C and data not shown). Indeed, TNF-a is
also an inducer of NF-kB activation in these cells, albeit to a lesser
extent than IL-1b [49]. C/EBPd was shown to auto-regulate its
expression by binding to sites located downstream of the C/EBPd
gene [43,50]. Unlike IL-1b, TNF-a alone does not up-regulate C/
EBPd expression (Figure 1B–C). It is thus conceivable that C/
EBPd transcription in b-cells is initiated by NF-kB and other
transcription factors induced by IL-1b (but not by TNF-a) and
that this initial synthesis of C/EBPd is required to allow further C/
EBPd-mediated auto-transcription. Interestingly, IL-1b+IFN-c-
induced C/EBPdmRNA up-regulation was sustained until 24 h of
cytokine treatment while the expression of C/EBPd protein
returned to basal after 16 h (Figs. 1 & 2). This may be explained by
the progressive increase of cytokine-induced ER-stress, previously
suggested to inhibit mRNA translation of many proteins in b-cells
[42].
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Inhibiting C/EBPd activity in b-cells exacerbates IL-1b+IFN-c-
induced apoptosis by increasing the expression of the pro-
apoptotic factors CHOP and BIM, while overexpressing C/EBPd
down-regulates CHOP and BIM expression and partially protects
b-cells against the deleterious effects of cytokines (Figure 3, 4 & 7).
This increased cytokine-induced apoptosis in C/EBPd-silenced
cells is independent of increased oxidative or nitrosative stress
(Figure 2G & S2D–E), and our preliminary experiments did not
Figure 6. The transcription factors STAT1 and CHOP mediate cytokine-induced BIM up-regulation in C/EBPd-silenced cells. INS-1E
cells were transfected with siCtrl (white bars), siC/EBPd #1 (black bars), siCHOP (grey bars), siSTAT1 (grid bars), siC/EBPd #1+siCHOP (hatched grey
bars), siC/EBPd #1+siSTAT1 (hatched bars) or siCHOP+siSTAT1 (grid grey bars) and subsequently left untreated or treated with IL-1b+IFN-c for 16 or
24 h as indicated. (A–D) CHOP, C/EBPd, STAT1 & BIM mRNA expressions were assayed by RT-PCR and normalized for the housekeeping gene GAPDH.
(E) 24 h after siRNA transfection, cells were transfected with a BIM promoter reporter+pRL-CMV and subsequently left untreated or exposed to
cytokines as indicated. Results are mean Relative Luciferase Unit (R.L.U.) 6 SEM. (F) Apoptosis was assessed by HO/PI staining. Results are mean 6
SEM of 4–5 experiments; *: p,0.05, **: p,0.01 and ***: p,0.001 vs untreated transfected with the same siRNA; 1: p,0.05, 11: p,0.01 and
111: p,0.001 vs siCtrl treated with cytokines at the same time point; #: p,0.05 and ###: p,0.001 vs siC/EBPd #1 treated with cytokines at the
same time point; ANOVA followed by Student’s t test with Bonferroni correction.
doi:10.1371/journal.pone.0031062.g006
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indicate a role of modified autophagy in this process (data not
shown). Autophagy has recently been suggested to be involved in
b-cell death in both type 1 & type 2 diabetes [51,52]. This negative
regulatory role of C/EBPd on cytokine-induced apoptosis in b-
cells appears to be critical and non-redundant, since it is conserved
between rodents and humans (Figures 1 and 2). This adds a new
dimension to C/EBPd functions, as previous reports described C/
EBPd mostly as a cell growth regulator and tumor suppressor.
Indeed, C/EBPd expression is down-regulated in acute myeloid
leukemia [53] and in cervical, breast and liver cancers [54,55],
while C/EBPd knockout mice display mammary gland ductal
hyperplasia [37]. These anti-proliferative activities in mammary
gland epithelial cells are linked to C/EBPd-induced Cdc27
expression, resulting in proteasome-mediated destruction of the
cell cycle promoting factor Cyclin D1 [38,56]. Putative tumor-
suppressing activities of C/EBPd may, however, depend on the
hormonal background, since C/EBPd is highly expressed in
androgen-dependent but not androgen-independent prostate
carcinomas [57]. These data underline the context dependency
of the function of regulatory transcription factors in different cell
types or hormonal backgrounds, and indicate two novel functions
for C/EBPd in primary non-dividing cells namely as an important
anti-apoptotic and anti-inflammatory regulator. Our preliminary
data on C/EBPb silencing suggest that C/EBPb does not play a
key role in IL-1b+IFN-c-induced b-cell death. This differs from
the previously reported effects of C/EBPb in ER-stress-induced b-
cell and tumoral cell death [41,58], palmitate-induced b-cell
apoptosis [59], and NO-dependent hepatocyte apoptosis [60]. On
the other hand, C/EBPb knockdown slightly decreases NO
production in INS-1E cells (present data), which is in accordance
with the reported roles of C/EBPa and C/EBPb for iNOS
induction in hepatocytes [60]. We cannot exclude that the
moderate (60%) C/EBPb silencing achieved in our experiments
was not sufficient to disclose the putative effect of the transcription
factor in cytokine-induced apoptosis. Additional experiments are
required to clarify this issue.
Our data suggest that increased CHOP and BIM expression in
C/EBPd-silenced cells contributes for the exacerbation of
apoptosis upon exposure to IL-1b+IFN-c. Indeed, concomitant
silencing of CHOP and C/EBPd or BIM and C/EBPd abrogates
the exacerbating effects of C/EBPd silencing on cytokine-induced
up-regulation of the rat BIM promoter and on cytokine-induced
apoptosis (present data). CHOP is a well known ER-stress-induced
transcription factor that may trigger apoptosis through perturba-
tion of intracellular pH and cellular cytoskeleton, down-regulation
of the anti-apoptotic factor Bcl-2 and increase of reactive oxygen
species production [61,62]. CHOP expression is regulated by
other C/EBP family members, including C/EBPa and C/EBPb
[63]. CHOP has been shown to hetero-dimerize with C/EBPa, b
and d [28,43,64], hence targeting these transcription factors to
Figure 7. C/EBPd overexpression decreases BIM expression and partially protect INS-1E cells against cytokine-induced apoptosis.
INS-1E cells were left untransfected (grey bars) or transfected with pCMV-Ctrl (white bars) or pCMV-C/EBPd (black bars) and subsequently left untreated
or treated with IL-1b+IFN-c for 16 or 24 h as indicated. (A) BIM, C/EBPd and a-tubulin expressions were evaluated by Western blot. (B) Mean optical
density measurements of BIMWestern blots corrected for a-tubulin (representative figure in A). (C–D) BIM and CHOPmRNA expressions were assayed by
RT-PCR and normalized for the housekeeping gene GAPDH. (E) Cells were co-tranfected with the vectors as decribed above and with a BIM promoter
reporter+pRL-CMV and subsequently left untreated or exposed to cytokines as indicated. Results are mean Relative Luciferase Unit (R.L.U.) 6 SEM; (F)
Apoptosis was assessed by HO/PI staining; (G) Cell viability was evaluated using the neutral red-based toxicology kit. Results are mean 6 SEM of 4–6
experiments; **: p,0.01 and ***: p,0.001 vs untreated untransfected or transfected with the same plasmid vector; 1: p,0.05,
11: p,0.01 and 111: p,0.001 vs pCMV-Ctrl treated with cytokines at the same time point; ANOVA followed by Student’s t test with Bonferroni correction.
doi:10.1371/journal.pone.0031062.g007
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specific DNA binding sequences [65]. The nature of the
interaction between C/EBPd and CHOP in cytokine-treated b-
cells and how C/EBPd deficiency enhances CHOP expression,
remain to be determined. Increased CHOP expression in C/
EBPd-silenced cells is associated with increased CHOP-regulated
transcription, since the expression of the CHOP-regulated pro-
apoptotic gene GADD34 [66] is also exacerbated in C/EBPd-
deficient cells (present data). Moreover, increased CHOP
expression enhances the expression of the pro-apoptotic Bcl-2
family member BIM in cytokine-treated C/EBPd-silenced cells
(see below). Previous reports indicate that BIM has an important
role in high glucose- [27], virus- [67] and cytokine-induced b-cell
death [26,68], which occurs through the mitochondrial apoptotic
pathway [23]. We presently show that the exacerbation of
cytokine-induced up-regulation of BIM mRNA and BIM
promoter activity in C/EBPd-silenced cells is at least in part
mediated by the transcription factors STAT1 and CHOP. BIM
up-regulation was already shown to be mediated by STAT1 in IL-
21-treated lymphocytic leukaemia cells [69] and TNF-a+IFN-c-
exposed b-cells [26], while CHOP activity is required for BIM up-
regulation and apoptosis induction in thapsigargin-treated thymo-
cytes [45] and growth factor-deprived lymphoid precursors [70].
Although BIM mRNA was up-regulated by cytokines at all time
points studied in siCtrl-tranfected cells, we observed a transient
decrease in BIM protein expression after 8 h of IL-1b+IFN-c
exposure (Figure 4C). This is not due to an off-target effect of the
siCtrl, as BIM protein also decreased after 8 h of cytokine
exposure in untransfected cells (Figure S5D–E). This transient
decrease in BIM protein expression was not observed in siC/
EBPd-silenced cells, in which exacerbated up-regulation of BIM
mRNA expression seems to allow constant BIM protein expression
throughout cytokine exposure. BIM has been reported to be
targeted to proteasome-mediated degradation during rapid
ischemic tolerance in neurons [71,72] and subjected to caspase
3-mediated degradation as a feedback mechanism in MEFs and
osteoclasts [73], but the putative pathways leading to BIM
degradation and re-synthesis in IL-1b+IFN-c-exposed b-cells
remain to be clarified. As a whole, our data suggest that IL-
1b+IFN-c-induced BIM up-regulation in b-cells is mediated
mostly via STAT1 activation, while CHOP seems to contribute
for the exacerbating effects of C/EBPd silencing on BIM
expression. Nonetheless, while C/EBPd overexpression repressed
to a large extent BIM expression in INS-1E cells, it only
moderately protected these cells against IL-1b+IFN-c-induced
apoptosis (Figure 7). These results emphasize the complexity of the
pro-apoptotic pathways induced by cytokines in b-cells and the
relative complementarity/redundancy of function of the pro-
apoptotic Bcl-2 family members in cytokine-exposed b-cells [23].
Cytokine-induced up-regulations of the chemokines CXCL1, 9,
10 and CCL20 mRNAs are all exacerbated in C/EBPd-silenced
cells, as is the release of the tested chemokines CXCL1 and
CXCL9, suggesting that C/EBPd elicit anti-inflammatory activ-
ities in b-cells. These observations contrast with previous reports,
describing C/EBPd as a pro-inflammatory transcription factor
that promotes LPS-induced activation of microglial cells and
astrocytes [74], participates in TLR-induced pro-inflammatory
cytokines production [39] and discriminates between transient and
persistent LPS-mediated signalling in macrophages [48]. On the
other hand, the anti-inflammatory agent dexamethasone was
shown to induce C/EBPd expression in skeletal muscle [57], while
amyloid-b fibrils down-regulate C/EBPd in astro-microglial cells
during Alzheimer’s disease [75]. We have previously shown that
cytokine-induced chemokine production is increased by the
prolongation of STAT1 activation in b-cells; IRF-1 controls a
negative regulatory feedback loop that limits STAT1 activation
through induction of the STAT1 regulator SOCS-1 [16]. In the
present experiments, prolonged IL-1b+IFN-c-induced STAT1
activation in C/EBPd-silenced cells was also associated with
defective induction of IRF-1 and its downstream gene SOCS-1,
and augmented chemokine production. Of note, C/EBPd
deficiency decreases NF-kB-dependent transcription in cytokine-
treated INS-1E cells. Since NF-kB is involved in cytokine-induced
IRF-1 expression [16,76] it is likely that C/EBPd activation
promotes IRF-1 expression by either participating directly to IRF-
1 transcription by dimerizing with NF-kB1 p50 or RelA, or by
inhibiting a negative regulator of NF-kB activation. The relation
between C/EBPd and IRF-1 expression remains to be clarified,
and the co-immunoprecipitation experiments that we performed
did not indicate a direct interaction between IRF-1 and C/EBPd
(data not shown), as it was previously reported for C/EBPb in
IFN-c-treated HepG2 cells [77].
We and others observed that b-cells have in place regulatory
mechanisms devoted to control excessive activation of deleterious
factors induced by cytokines. These include PTPN2- and IRF-1/
SOCS-1-mediated attenuation of STAT1 activation [16,78],
JunB-mediated attenuation of NO production and ER stress
[79], A20- and SOCS-3-mediated NF-kB inactivation [80,81] and
HSP70 synthesis upon cytokine-treatment [82]. It is likely that C/
EBPd contributes to these signalling pathways that provide ‘‘local’’
regulation to inflammatory processes in order to protect poorly
proliferating and long-lived cells, such as b-cells, against excessive
damage. It remains to be clarified why these regulatory
mechanisms are overruled in T1D, but the identification of novel
agents that selectively promote protective pathways in b-cells may
Figure 8. Suggested model for the role of C/EBPd signalling in
cytokine-treated b-cells. Transcription factors are highlighted in
circle, thin arrows represents positive (inducing) effects, while bold T-
shaped lines represent inhibitory effects. Upon IL-1b+IFN-c exposure, C/
EBPd is up-regulated downstream of the transcription factors NF-kB and
STAT1. Once synthesized, it inhibits CHOP and BIM expression,
hampering cytokine-induced caspase 9 and 3 cleavage and apoptosis.
C/EBPd also exerts a positive role on cytokine-induced IRF-1 expression,
which, via the induction of the regulator SOCS-1, down-regulates STAT1
activation and STAT1-driven chemokine production.
doi:10.1371/journal.pone.0031062.g008
C/EBPd Regulates Cytokine-Induced b-Cell Death
PLoS ONE | www.plosone.org 11 February 2012 | Volume 7 | Issue 2 | e31062
represent an alternative and ‘‘local’’ approach to protect b-cells
against the relentless destructive assault initiated by autoimmune
cells.
Materials and Methods
Culture of primary FACS-sorted rat b-cells, human islets
and INS-1E cells
Male Wistar rats (Charles River Laboratories, Brussels,
Belgium) were housed and used according to the guidelines of
the Belgian Regulations for Animal Care; all experiments
performed have been approved by the CEBEA Ethical Committee
(Commission d’Ethique du Bien-Etre Animal, Universite Libre de
Bruxelles, Permit Number LA 1230351, valid until 2014). For islet
isolation, pancreases were digested by collagenase and islets were
hand picked under a stereomicroscope. B-cells were purified by
autofluorescence-activated cell sorting (FACSAria, BD Bioscience,
San Jose, CA, USA) [83]. The preparations contained 9562% b-
cells (n=9). b-cells were cultured for 2 days in Ham’s F-10
medium containing 10 mM glucose, 2 mM glutaMAX, 50 mM 3-
isobutyl-1-methylxanthine, 5% FBS, 0.5% charcoal-absorbed BSA
(Boehringer, Indianapolis, IN, USA), 50 U/ml penicillin and
50 mg/ml streptomycin [83]. During cytokine exposure, cells were
cultured in the same medium but without serum.
Human islets were isolated from 10 non-diabetic organ donors
(age 6564 years; body mass index 26.161 kg/m2) in Pisa, Italy,
with the approval of the Ethics Committee of the University of
Pisa. A written consent was obtained from each organ donor for
the use of the pancreas for research purposes. Islets were isolated
by enzymatic digestion, density-gradient purification [84], and
cultured in M199 medium containing 5.5 mM glucose. The
human islets were shipped to Brussels within 1–5 days of isolation.
After overnight recovery in Ham’s F-10 containing 6.1 mM
glucose, 10% FBS, 2 mM GlutaMAX, 50 mM 3-isobutyl-1-
methylxanthine, 1% BSA, 50 U/ml penicillin and 50 mg/ml
streptomycin, islets were dispersed for viability assays or exposed
to cytokines in the same medium without FBS for 24 h. The
percentage of b-cells, examined in the 10 dispersed islet
preparations by staining with anti-insulin antibody (1:1000, Sigma,
Bornem, Belgium) and donkey anti-mouse IgG rhodamine (1:200,
Lucron Bioproducts, De Pinte, Belgium), was 6365%; only
preparations containing .40% b-cells were used in the experi-
ments.
The rat insulin-producing INS-1E cell line (a kind gift from Dr.
C. Wollheim, Centre Medical Universitaire, Geneva, Switzerland)
was cultured as previously described [85] and used between
passages 52 and 72.
RNA interference
The following: siRNAs were used (sequence 59-39): BLOCK-iT
StealthTM Select siRNA (Invitrogen, Paisley, UK) for rat siC/
EBPd #2 CCGACCUCUUCAACAGCAAUCACAA, human
siC/EBPd #1 ACAGCCUGGACUUACCACCACUAAA, hu-
man siC/EBPd#2 GCCUCCGGCAGUUCUUCAAGCAGCU,
human siC/EBPd #3 CGAGAGAAGCUAAACGUGUUUAU-
UU, rat siSTAT1 CCCUAGAAGACUUACAAGAUGAAUA,
rat siBIM CGAGGAGGGCGUUUGCAAACGAUUA; ON-
TARGETplus SMARTpoolH (Thermo Scientific, Chicago, IL,
USA) for rat siC/EBPd #1 Seq. #1 CGCAGACAGUGGU-
GAGCUU Seq. #2 CGACUUCAGCGCCUACAUU Seq. #3
GAUCUUCGCCGACCUCUUC Seq. #4 CCACGACCCCU-
GCCAUGUA and rat siCHOP Seq. #1 GGAAGAACUAG-
GAAACGGA Seq. #2 GGGCUCUGAUCGACCGCAU Seq.
#3 CUGAAGAGAACGAGCGGCU Seq. #4 ACGAGGA-
AAUCGAGCGCCU; Silencer Select Pre-designed siRNA for
rat siC/EBPb #1 CUAUUUCUAUGAGAAAAGAtt, rat siC/
EBPb #2 GCAUUAAAGUGAAGACAUUtt. Allstars Negative
Control siRNA was used for control-transfected conditions
(Qiagen, Venlo, The Netherlands, sequence not provided). The
concentration of siRNA used for cell transfection (30 nM) was
selected based on previous dose-response studies [78,86]; neither
transfection nor the control siRNA affect b-cell viability, function
or gene expression as compared to non-transfected b-cells
[16,17,78]. In co-transfection experiments 30 nM of each active
siRNA was used while 60 nM siCtrl siRNA was transfected in the
control condition. Lipofectamine RNAiMAX lipid reagent
(Invitrogen) was used for siRNA transfection, following the
previously described protocol [78]. After transfection, cells were
cultured for a 48 h recovery period and subsequently exposed to
cytokines.
Cell treatment and NO measurement
The following cytokine concentrations were used, based on
previous dose-response experiments [8,85,87]: recombinant hu-
man IL-1b (specific activity 1.86107 units/mg; a gift from C.W.
Reinolds, National Cancer Institute, Bethesda, MD) at 10 units/
ml (for rat cells) or 50 units/ml (for human cells); recombinant
murine TNF-a (specific activity: 26108 units/mg; Innogenetics,
Gent, Belgium) at 1,000 units/ml; and recombinant rat or human
IFN-c (specific activity: 26107 units/mg; R&D Systems, Abing-
don, U.K.) at 100 and 1,000 units/ml for rat cells and human islets
respectively. Culture supernatants were collected for nitrite
determination (nitrite is a stable product of NO oxidation) at
OD540 nm using the Griess method.
Evaluation of intracellular ROS/RNS content
Cells were transfected with siCtrl, siC/EBPd #1 or siC/EBPd
#2 and left untreated or treated as described above for 2–24 h
with IL-1b+IFN-c. Cells were then lysed in PBS by freeze/thaw
cycles followed by sonication. Cell lysates were centrifuged to
discard cellular debris and lysates were quantified using the
Bradfod method. Intracellular ROS/RNS content was then
evaluated in an equivalent amount of cell extract for each
condition using the OxiSelect in vitro ROS/RNS assay kit (Green
Fluorescence - Cell Biolabs, San Diego, CA, USA).
Western blots
Cells were washed, lysed, extracts were resolved by 10–14%
SDS-PAGE and transferred to a nitrocellulose membrane as
described [78]. The antibodies used were: anti-C/EBPd (sc-636),
anti-STAT1 (sc-346), anti-CHOP (GADD153 – sc-575) and anti-
IRF-1 (sc-640) from Santa Cruz Biotechnology (Santa Cruz, CA,
USA); anti-phospho-STAT1 (Y701 - #9171), anti-BIM (#2819),
anti-HSP60 (#4870), anti-cleaved caspase 3 (#9661) and anti-
cleaved caspase 9 (#9507) from Cell Signalling (Danvers, MA,
USA); anti ClpP (15698-1-AP) and anti-LONP1 (15440-1-AP)
from Proteintech (Manchester; UK); anti-a-tubulin (T9026) from
Sigma (Bornem, Belgium). HRP-conjugated anti-rabbit or anti-
mouse IgG (Lucron Bioproducts, De Pinte, Belgium) were used as
secondary antibodies. Immunoreactive bands were revealed using
the SuperSignal West Femto chemiluminescent substrate (Thermo
Scientific), detected using a LAS-3000 CCD camera and
quantified with the Aida Analysis software (Fujifilm).
mRNA extraction and real time PCR
Poly(A)+ mRNA was isolated from INS-1E cells or rat primary
b-cells using the Dynabeads mRNA DIRECTTM kit (Invitrogen),
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and reverse transcribed as previously described [83]. The real time
PCR amplification reaction was done as described [83], using
SYBR Green and compared to a standard curve. Expression
values were corrected for the housekeeping genes glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) and b-actin for rat and
human assays respectively; we have previously shown that
cytokines do not modify GAPDH and b-actin expressions in these
species [78]. The primers used in this study are listed in Table S1.
Assessment of apoptosis and viability
The percentage of viable, apoptotic and necrotic cells was
determined after staining with the DNA-binding dyes Propi-
dium Iodide (PI, 5 mg/ml, Sigma) and Hoechst 33342 (HO,
5 mg/ml, Sigma) [83]. This method is quantitative, and has
been validated by systematic comparison against electron
microscopy [88] and several other well-characterized methods,
including fluorometric caspase 3 & 7 assays and determination
of histone-complexed DNA fragments by ELISA [24,25,89–91].
A minimum of 500 cells was counted in each experimental
condition. Viability was evaluated by two independent observ-
ers, one of them being unaware of sample identity. The
agreement between findings obtained by the two observers was
.90%. Results are expressed as percent apoptosis, calculated as
(number of apoptotic cells/total number of cells)6100. Apop-
tosis was confirmed in some experiments by the Cell Death
Detection ELISAplus kit (Roche Diagnostics, Vilvoorde, Bel-
gium), which detects cytoplasmic fragmented DNA. For some
key experiments, cellular viability after cytokine treatment was
assessed using the Neutral Red-based in vitro toxicology assay kit
(Sigma) as follows: neutral red (final concentration 33%) was
added to the culture medium for 2 h before the end of cytokine
treatment. The culture medium was then removed and cells
were washed once with the fixative solution to discard detached
cells and remove unincorporated neutral red. The neutral red
incorporated into living cells was then eluted using the
solubilisation solution. ODs were read at 540 nm; the
magnitude of the OD540 nm is directly proportional to the
number of remaining living cells for each condition.
Luciferase reporter assay and immunofluorescence
INS-1E cells were transfected as previously described [49]
with pRL-CMV encoding Renilla luciferase (Promega) and
either a luciferase promoter-reporter construct containing 3
GAS consensus sequences (STAT1 reporter) or 5 NF-kB
consensus binding sites (NF-kB reporter) or the fragment
(22545/+2658) from the rat BIM promoter (BIM promoter
experiments – a kind gift of Pr. M. Li, Sun Yat-sen University,
China) [47]. Luciferase activities were assayed after 16–24 h of
cytokine treatment [49].
For immunofluorescence studies, INS-1E cells were seeded
onto polylysine-coated glass coverslips and treated as indicated.
Cells were washed with cold PBS, fixed for 10 min in 4%
paraformeldehyde and permeabilized for 5 min in PBS contain-
ing 0.1% Triton X-100 (PBST). Following a 1 h blocking with
5% normal goat serum (NGS) in PBST, cells were incubated
overnight with the following primary antibodies diluted at 1/
1000 in PBST 5% NGS: anti-Bax (sc-493, Santa Cruz
Biotechnology), anti-AIF (#4642, Cell Signaling), anti-ATP
synthase b (A9728, Sigma) or mouse anti-cytochrome c (#
556432, BD Pharmingen, San Jose, CA, USA). Cells were
washed three times with PBS and DyLight488-conjugated donkey
anti-mouse and DyLight549-conjugated donkey anti-rabbit anti-
bodies (Lucron Bioproducts) were applied for 2 h at 1:1000 in
PBST. After 2 washes with PBST, nuclei were counterstained
with Hoechst 33342 (HO) for 5 min, and washed 3 times with
PBS. Coverslips were mounted in 50% glycerol, and immuno-
fluorescence was visualized on a Zeiss Axiovert 200 microscope
(Oberkochen, Germany).
Glucose oxidation assay
D-[U-14C] glucose (specific activity: 300 mCi/mmol, concen-
tration: 1 mCi/ml, Perkin Elmer, Waltham, MA) was used to
evaluate glucose oxidation in untreated and IL-1b+IFN-c-treated
siCtrl- or siC/EBPd-transfected cells. Cells were trypsinized and
resuspended in KRBH solution without glucose at 56106 living
cells/ml. 20 ml of the cell suspension (1.105 cells) was transferred to
glass vials containing 20 ml KRBH buffer supplemented with
0.19 mCi of D-[U-14C] glucose and non-radioactive glucose to a
final concentration of 1.67, 10 or 16.7 mM of glucose. The vials
were inserted into 20 ml glass scintillation flasks, gassed with 95%
CO2 and 5% O2, airtight sealed with rubber membranes and
shaken continuously for 2 h at 37uC. After incubation, 0.02 ml of
metabolic poison (400 mM citrate buffer - pH 4.9, 3 mM KCN,
10 mM Antimycin A, 20 mM Rotenone; pH 7.4) was injected
through the rubber cap into the vials containing the cells and
0.2 ml hyamine hydroxide was injected outside of the vials to
absorb the released CO2. Following 1 h incubation at 37uC, the
vials were removed and scintillation fluid (6 ml) was added to the
hyamine. After 14 h at 4uC, the radioactivity was measured in a
TriCarb 2100TR Liquid scintillation analyzer (Perkin Elmer,
Waltham, MA). The rate of glucose oxidation was expressed as
mmol/120 min.1000 cells.
Infection with recombinant adenoviruses
Cells were infected either with Ad-Luc (luciferase-expressing
adenovirus) or Ad-srIkB (a virus expressing an NF-kB super-
repressor IkBa protein) [40]. Cells were infected for 2 h at 37uC
with a multiplicity of infection (MOI) of 10. The MOI was selected
based on lowest toxicity by viral infection combined with highest
blockade of NF-kB activation. After infection (24 h), cells were
treated with cytokines. We have previously shown that infection of
b-cells with Ad-srIkB at the MOI used in the present study does
not change its function or viability [40].
Overexpression of rat C/EBPd
The expression vectors pCMV-Ctrl [16] and pCMV-C/EBPd
(TrueORF cDNA Clones - OriGene, Rockville, MD, USA) were
transfected in INS-1E cells using Lipofectamine 2000 (Invitrogen)
as previously described [49]. After overnight incubation, the
medium was changed and cells were exposed to cytokines as
indicated.
Evaluation of chemokine accumulation in the medium by
ELISAs
Cells were transfected with siCtrl, siC/EBPd #1 or siC/EBPd
#2 and subsequently left untreated or treated with IL-1b+IFN-c
as described above. Supernatants were collected after 2, 4, 8, 16 &
24 h of treatment for determination of CXCL1 and CXCL9
chemokines secretion using the commercially available ELISA kits
for rat CXCL1 (R&D Systems) and rat CXCL9 (Uscn Life
Science, Wuhan, China).
Statistical analysis
Data are presented as mean 6 SEM. Comparisons were
performed by two-tailed paired Student’s t-test or by ANOVA
followed by Student’s t test with Bonferroni correction as
indicated. A p value,0.05 was considered statistically significant.
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Supporting Information
Figure S1 IL-1b and IFN-c up-regulate C/EBPd expres-
sion in INS-1E cells and primary FACS-sorted rat b-cells.
(A) INS-1E cells were left untreated or treated for 8 h with either
IL-1b, IFN-c, TNF-a, IL-1b+IFN-c or TNF-a+IFN-c. The figure
represents mean optical density measurements of C/EBPd
Western blots corrected for a-tubulin (representative figure in
Figure 1C). (B) Primary purified rat b-cells were left untreated or
treated with the combination of TNF-a+IFN-c for 24 h; C/EBPd
mRNA expression was assayed by RT-PCR and normalized for
the housekeeping gene GAPDH. (C) INS-1E cells were infected
with Ad-Luc or Ad-srIkB and subsequently treated with cytokines
as indicated. (D) INS-1E cells were transfected with siCtrl (white
dots) or siSTAT1 (black triangles) and subsequently left untreated,
or treated with IL-1b+IFN-c for 12- or 24 h as indicated. (C–D)
C/EBPd mRNA expression were assayed by RT-PCR and
normalized for the housekeeping gene GAPDH. Results are mean
6 SEM of 4–5 independent experiments; *: p,0.05, **: p,0.01
and ***: p,0.001 vs untreated (transfected with the same siRNA);
1: p,0.05 and 11: p,0.01 vs siCtrl treated with cytokines at the
same time point; ANOVA followed by Student’s t test with
Bonferroni correction.
(TIF)
Figure S2 C/EBPd-silencing neither exacerbates IL-1b-
or IFN-c-induced apoptosis nor aggravates cytokine-
induced inhibition of glucose oxidation in INS-1E cells.
(A–E) INS-1E cells were transfected with either siCtrl (white dots/
bars), siC/EBPd #1 (black triangles/bars) or siC/EBPd #2 (grey
squares/bars) and subsequently left untreated, or treated with
either IL-1b, IFN-c, TNF-a, IL-1b+IFN-c or TNF-a+IFN-c for
the indicated time point. (A–B) Apoptosis was assessed by HO/PI
staining after 24 h; (C) Cell viability was evaluated using the
neutral red-based toxicology kit. (D) Nitrite production was
evaluated as described in Materials & Methods; (E) ROS and
RNS content was evaluated as described in Materials & Methods.
(F) HeLa cells were transfected with siCtrl or 3 siRNAs targeting
human C/EBPd (#1, #2 & #3) and subsequently left untreated
or treated with IL-1b+IFN-c for 8 h. C/EBPd and a-tubulin
expressions were evaluated by Western blot. (G–H) INS-1E cells
were transfected with rat siC/EBPd #1 and subsequently treated
with IL-1b+IFN-c for 16 h. Cells were fixed and processed for
immunofluorescence as described in Methods; A: apoptotic cell, L:
living cell. The figure is representative of 5 independent
experiments. (I–J) Mean optical density measurements of cleaved
caspase 3 & 9 Western blots corrected for a-tubulin (representative
figure in Figure 2I). (K) Glucose oxidation assay was performed as
described in Materials & Methods. Results are mean 6 SEM
of 4–5 independent experiments; *: p,0.05, **: p,0.01 and
***: p,0.001 vs untreated transfected with the same siRNA;
1: p,0.05, 11: p,0.01 and 111: p,0.001 vs siCtrl treated with
cytokines at the same time point; ANOVA followed by Student’s t
test with Bonferroni correction.
(TIF)
Figure S3 C/EBPb silencing doesn’t affect IL-1b+IFN-c-
induced apoptosis and nitrite production in INS-1E
cells. (A) INS-1E cells were left untreated or treated with the
combination of IL-1b+IFN-c for 12 or 24 h as indicated and C/
EBPbmRNA expression was assayed by RT-PCR and normalized
for the housekeeping gene GAPDH. (B–D) INS-1E cells were
transfected with siCtrl (white bars), siC/EBPb #1 (black bars) or
siC/EBPb #2 (grey bars) and subsequently left untreated, or
treated with IL-1b+IFN-c for 24 h as indicated. (B) C/EBPb
mRNA expression was assayed by RT-PCR and normalized
for the housekeeping gene GAPDH. (C) Apoptosis was assessed
by HO/PI staining. (D) Nitrite production was evaluated as
described in Materials & Methods. Results are mean 6 SEM of 4
independent experiments; *: p,0.05, **: p,0.01 and ***: p,0.001
vs untreated transfected with the same siRNA; 1: p,0.05 and
11: p,0.01 vs siCtrl treated with cytokines at the same time point;
ANOVA followed by Student’s t test with Bonferroni correction.
(TIF)
Figure S4 Expressions of XBP-1s, BIP and the UPRmt
markers are unaffected by C/EBPd silencing in INS-1E
cells. (A–C) INS-1E cells were transfected with siCtrl (white dots),
siC/EBPd#1 (black triangles) or siC/EBPd #2 (grey squares) and
subsequently left untreated, or treated with IL-1b+IFN-c for the
indicated time points. (A–B) XBP-1s and BIP mRNA expression
were assayed by RT-PCR and normalized for the housekeeping
gene GAPDH. (C) The UPRmt markers LONP1, HSP60, ClpP
and a-tubulin expressions were evaluated by Western blot; the
figure shown is representative of 3 independent experiments.
Results in Figs. 4A & 4B are mean 6 SEM of 4 independent
experiments; **: p,0.01 and ***: p,0.001 vs untreated transfected
with the same siRNA; ANOVA followed by Student’s t test with
Bonferroni correction.
(TIF)
Figure S5 C/EBPd knockdown doesn’t affect cytokine-
induced up-regulation of DP5, PUMA and Bcl-XL in INS-
1E cells. (A–C) INS-1E cells were transfected with siCtrl (white
dots), siC/EBPd #1 (black triangles) or siC/EBPd #2 (grey
squares) and subsequently left untreated or treated with IL-
1b+IFN-c for the indicated time points. DP5, PUMA and Bcl-XL
expressions were assayed by RT-PCR and normalized for the
housekeeping gene GAPDH. (D–E) INS-1E cells were left
untransfected (grey dots) or transfected with siCtrl (white dots)
and subsequently left untreated or treated with IL-1b+IFN-c for
the indicated time points. (D) BIM and a-tubulin expression were
evaluated by Western blot. (E) Mean optical density measurements
of BIMWestern blots corrected for a-tubulin (representative figure
in E). Results are mean 6 SEM of 4–5 independent experiments;
*: p,0.05, **: p,0.01 and ***: p,0.001 vs untreated untrans-
fected or transfected with the same siRNA; ANOVA followed by
Student’s t test with Bonferroni correction.
(TIF)
Figure S6 C/EBPd silencing decreases the activation of
an NF-kB luciferase reporter. INS-1E cells were transfected
with siCtrl (white bars), siC/EBPd #1 (black bars) or siC/EBPd
#2 (grey bars). After 24 h, cells were transfected with a NF-kB
luciferase reporter+pRL-CMV and subsequently left untreated or
exposed to IL-1b+IFN-c for 16 h as indicated. Results are mean
Relative Luciferase Unit (R.L.U.) 6 SEM of 5 independent
experiments; ***: p,0.001 vs untreated transfected with the same
siRNA; 11: p,0.01 and 111: p,0.001 vs siCtrl treated with
cytokines at the same time point; ANOVA followed by Student’s t
test with Bonferroni correction.
(TIF)
Table S1 List of primers used for real time PCR.
(TIF)
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